Alligator Bioscience AB: Year-end Report January-December 2020

Continued focus on clinical development.

“Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with metastatic cancer. The results show a promising safety profile with only minor drug-related side effects.” 

Per Norlén, CEO Alligator Bioscience 


•    New preclinical comparative data showed that mitazalimab has highly competitive immunostimulatory characteristics.
•    IND approved for forthcoming clinical studies in the US.
•    CTA submitted for launch of the forthcoming Phase II study in pancreatic cancer.

•    Predicted therapeutic range dose levels reached in ongoing Phase I study.
•    Data Review Committee approved start of dosing at 200 mg, corresponding to approximately 3 mg/kg.

•    Alligator Bioscience and Aptevo Therapeutics commenced preparations for start of Phase I. 

•    ALLIGATOR-FAB™ antibody library launched.


•    Oversubscribed rights issue generated proceeds of SEK 86 million before transaction costs. 



October-December 2020 
•    Net sales, SEK 0.0 million (0.0). 
•    Operating result, SEK -34.1 million (-59.3).
•    Result for the period, SEK -34.5 million (-59.8).
•    Earnings per share before and after dilution, SEK -0.48 (-0.84).
•    Cash flow for the period, SEK -33.2 million (8.6). 
•    Cash and cash equivalents, incl. interest-bearing securities, SEK 103.3 million (249.9). 

January-December 2020
•    Net sales, SEK 4.4 million (4.4). 
•    Operating result, SEK -144.3 million (-214.5). 
•    Result for the period, SEK -143.3 million (-210.1). 
•    Earnings per share before and after dilution, SEK -2.01 (-2.94).
•    Cash flow for the period, SEK 9.4 million (-19.6).

During the first quarter, the holdings in corporate bonds and interest funds were divested, which had a positive effect on cash flow.

The full report is attached as PDF available on the company’s website:

Conference call/webcast 
Alligator will host a conference call today, February 26, 2021, at 2:00 p.m. CEST for investors, analysts and media, where CEO Per Norlén and CFO Marie Svensson will present and comment on the Year-end Report. The conference will be held in English. 

The conference call will be broadcast live on the web via the link:

Telephone number for the conference call is:
SE: +46850558358 
UK: +443333009266 
US: +18335268382

For further information, please contact:
Per Norlén, CEO
Phone: +46 46 540 82 00

Marie Svensson, CFO
Phone: +46 46 540 82 03

The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 a.m. CET on February 26, 2021.

About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s pipeline includes the two key assets ATOR-1017 and mitazalimab. Furthermore, there are two partnered assets: ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and AC101 in clinical development by Shanghai Henlius Biotech Inc. In addition, the company has developed a novel concept for more patient-specific immunotherapy: Neo-X-Prime. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden. For more information, please visit

Updated 2021-02-26